Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CYT 103; Indium 111In-satumomab pendetide; OncoScint CR/OV; OncoScint CR103; OncoScint OV103; satumomab pendetide

Latest Information Update: 14 May 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytogen Corporation
  • Class Acetic acids; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Oligopeptides; Polyamines; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Ovarian cancer

Most Recent Events

  • 09 May 2008 Cytogen Corporation is acquired by EUSA Pharma
  • 31 Aug 2004 Aventis merges with Sanofi-Synthelabo to form Sanofi-Aventis
  • 31 Dec 2002 Cytogen discontinues selling satumomab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top